Therapy of Helicobacter pylori

被引：37

作者：

McLoughlin, R ^{[1
]}

Racz, I

Buckley, M

O'Connor, HJ

O'Morain, C

机构：

[1] Adelaide & Meath Hosp, Dept Gastroenterol, Dublin 24, Ireland

[2] Trinity Coll Dublin, Dublin, Ireland

[3] Petz Aladar Teaching & Cty Hosp, Dept Internal Med & Gastroenterol 1, H-9024 Gyor, Hungary

来源：

HELICOBACTER | 2004年 / 9卷

关键词：

antibiotics; H; pylori; resistance; review; treatment;

D O I：

10.1111/j.1083-4389.2004.00251.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

This represents an overview of the main data published over the last year on the therapy of Helicobacter pylori. The problem of increasing failure of H. pylori eradication has been the main focus, with increasing resistance and poor patient compliance being the main culprits. Simple regimens are necessary to improve patient compliance. New antibiotics and novel agents are appraised with mixed results.

引用

页码：42 / 48

页数：7

共 40 条

[1] Inhibition of Helicobacter pylori growth in vitro by Bulgarian propolis:: preliminary report [J].

Boyanova, L ;

Derejian, S ;

Koumanova, R ;

Katsarov, N ;

Gergova, G ;

Mitov, I ;

Nikolov, R ;

Krastev, Z .

JOURNAL OF MEDICAL MICROBIOLOGY, 2003, 52 (05) :417-419

[2] Risk factors for failure of Helicobacter pylori therapy -: results of an individual data analysis of 2751 patients [J].

Broutet, N ;

Tchamgoué, S ;

Pereira, E ;

Lamouliatte, H ;

Salamon, R ;

Mégraud, F .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (01) :99-109

[3] Helicobacter pylori in children and adolescents:: Increase of primary clarithromycin resistance, 1997-2000 [J].

Crone, J ;

Granditsch, G ;

Huber, WD ;

Binder, C ;

Innerhofer, A ;

Amann, G ;

Hirschl, AM .

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2003, 36 (03) :368-371

[4]

de Boer SY, 2003, NETH J MED, V61, P218

[5] Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure [J].

De Francesco, V ;

Zullo, A ;

Margiotta, M ;

Marangi, S ;

Burattini, O ;

Berloco, P ;

Russo, F ;

Barone, M ;

Di Leo, A ;

Minenna, MF ;

Stoppino, V ;

Morini, S ;

Panella, C ;

Francavilla, A ;

Ierardi, E .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (04) :407-414

[6] Use of lactoferrin for Helicobacter pylori eradication -: Preliminary results [J].

Di Mario, F ;

Aragona, G ;

Dal Bò, N ;

Ingegnoli, A ;

Cavestro, GM ;

Moussa, AM ;

Iori, V ;

Leandro, G ;

Pilotto, A ;

Franzè, A .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2003, 36 (05) :396-398

[7] Effects of rebamipide, a gastro-protective drug on the Helicobacter pylori status and inflammation in the gastric mucosa of patients with gastric ulcer:: a randomized double-blind placebo-controlled multicentre trial [J].

Fujioka, T ;

Arakawa, T ;

Shimoyama, T ;

Yoshikawa, T ;

Itoh, M ;

Asaka, M ;

Ishii, H ;

Kuwayama, H ;

Sato, R ;

Kawai, S ;

Takemoto, T ;

Kobayashi, K .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 :146-152

[8] Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract [J].

Genta, RM .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 :8-13

[9] 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures [J].

Gisbert, JP ;

Calvet, X ;

Bujanda, L ;

Marcos, S ;

Gisbert, JL ;

Pajares, JM .

HELICOBACTER, 2003, 8 (02) :90-94

[10] Meta-analysis:: proton pump inhibitors vs. H2-receptor antagonists -: their efficacy with antibiotics in Helicobacter pylori eradication [J].

Gisbert, JP ;

Khorrami, S ;

Calvet, X ;

Gabriel, R ;

Carballo, F ;

Pajares, JM .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (08) :757-766

← 1 2 3 4 →